Across the US, roughly 1 in 10 adults struggle with alcohol use disorder — a medical condition that makes quitting feel ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told an ...

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. The secondary endpoints included weight loss, and, here again, orforglipron demonstrated ...

For years, the pancreas has been being taught in biology class as an easy system: insulin lowers blood sugar, and glucagon raises it. But that’s much too simple, new research says.

The popularity of GLP-1 drugs for weight loss continues to rise. About one in eight adults in the U.S. has tried medications ...

A former Ozempic user who quit the medication due to insurance issues claimed to have gained all their 'weight' back in just eight months.

Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...

Jabby is a newly launched iOS application for GLP-1 injection tracking, developed following extensive beta testing with over 3,000 users. The app provides comprehensive tools for patients managing ...

Discover how FTIR spectroscopy enhances quality control in GLP-1 weight loss drug production by ensuring molecular ...

Over the past two years, drugs like Ozempic and Mounjaro have gone from quiet prescriptions for Type 2 diabetes to global household names. Thanks to celebrity testimonials, viral TikToks and endless ...

The GLP-1 food market is booming, with global value hitting $53bn and major brands like Nestlé and General Mills launching ...